RTRX Stock News 12.52 05/13/2014 11:13:26 Desert Gateway Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Desert Gateway Inc. (RTRX) 12.52 $RTRX

Retrophin to Report First Quarter 2014 Financial Results
Business Wire - Mon May 12, 1:45PM CDT
Retrophin, Inc. (NASDAQ:RTRX) announced today that it will report its first quarter 2014 financial results on Wednesday, May 14, 2014. The press release will be followed by a conference call and webcast at 8:30 a.m. ET.

Retrophin Initiates Global Access for RE-024 in Pantothenate Kinase-Associated Neurodegeneration (PKAN)
Business Wire - Mon May 12, 7:01AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced that it has made RE-024 available to physicians who are treating critically ill patients with pantothenate kinase-associated neurodegeneration (PKAN) worldwide under local "compassionate use" regulations. RE-024 is a replacement therapy for phosphopantothenate, the reaction product and substrate that is missing in patients with PKAN.

Biotech Stocks Review -- Research on Retrophin, Merrimack, Gilead Sciences, and Rexahn Pharma
PR Newswire - Tue May 06, 11:37AM CDT
The U.S. markets on Monday, May 5, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the session 0.19% higher at 1,884.66. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, with the index advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Retrophin Inc. (NASDAQ: RTRX), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Gilead Sciences Inc. (NASDAQ: GILD) and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Free technical research on RTRX, MACK, GILD and RNN can be downloaded upon signing up at:

Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate Updates - Analyst Notes on Insmed, Akebia, Retrophin, Agios and Spectranetics
PR Newswire - Wed Apr 23, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Akebia Therapeutics, Inc. (NASDAQ: AKBA), Retrophin, Inc. (NASDAQ: RTRX), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and The Spectranetics Corporation (NASDAQ: SPNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1455-100free.

Should You Get Rid of Retrophin (RTRX) Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:41AM CDT
Retrophin (RTRX) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter as well as the current year.

Strength Seen in Retrophin, Inc. (RTRX) as Stock Shoots up 18% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 7:44AM CDT
Retrophin, Inc. was a big mover last session, as the company saw its shares surge ahead 18% on the day.

Nasdaq stocks posting largest percentage increases
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

Retrophin Updates Financial Guidance for 2014 and 2015 and Provides Corporate Update
Business Wire - Mon Apr 14, 6:00AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced it is updating its revenue outlook for 2014 and 2015.

FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, Steris, Retrophin, and NxStage Medical
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick" announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst.

3 Biotech Stocks Rising on Unusual Volume
at The Street - Tue Apr 01, 5:00AM CDT
Keep these biotech stocks on your radar.

Retrophin Reports Full-Year 2013 Financial Results
Business Wire - Thu Mar 27, 8:11AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today reported its financial results for the year ended December 31, 2013.

The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs

Retrophin Completes Acquisition of Manchester Pharmaceuticals
Business Wire - Thu Mar 27, 7:01AM CDT
Retrophin, Inc. (NASDAQ:RTRX) today announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5 million, including an upfront payment of $29.5 million, plus other payments based on product sales.

Retrophin (RTRX) Catches Eye: Stock Moves 7.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 26, 8:54AM CDT
Retrophin was a big mover last session, with shares rising nearly 8% on the day.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Habitat for Humanity AZ's Unique Gala: An Overview

Updated Category News Views 56

Mark Your Calendars: A Night to Celebrate Listen up, Central Arizona, because I'm giving you the lowdown on Habitat for Humanity Central Arizona's big night out. "Blueprints & Blue Jeans" - it's the gala that's ditching the formalities for some good old-fashioned community fun, but with a seriously important mission at its heart. Mark your calendars for Friday, March 5,...

Continue Reading
Radiation Oncology Text Earns Doody's 2026 Nod

Updated Category News Views 122

Recognition in Radiation Oncology In the rapidly advancing arena of radiation oncology, staying current is no small feat. But here's a feather in the cap of one publication doing just that: Fundamentals of Radiation Oncology: Physical, Biological, and Clinical Aspects, 4th Edition. This resource has made quite the splash by snagging a spot on the 2026 Doody's Core Titles...

Continue Reading
Blue Owl Tech Faces Lawsuit Post-44% Share Dive

Updated Category News Views 59

The air's thick with tension for investors of Blue Owl Technology Finance Corp. (NYSE:OTF) as they wake up to the news of a securities class action lawsuit that's no small fry. You don’t have to look too far to see why the folks holding the bag might be steamed. We’re talking about a 44% drop in stock price since the merger with Blue Owl Technology Finance Corp....

Continue Reading
TELUS Targets Debt Reduction Amid Telecom Transformation

Updated Category News Views 99

Adjusting Strategy Amid Financial Challenges The market's a tough beast, and TELUS seems to be wrestling with it, showing both grit and foresight in its latest quarterly update. Third quarter 2026 has TELUS down on revenues with a notable net loss but don't count them out yet. Their Transformation Strategy is a gamble worth watching. Where the Numbers Stand Here's the...

Continue Reading
Havertys Dividend: A Steady Payout Tradition Continues

Updated Category News Views 87

Another Year, Another Dividend for Havertys Man, talk about a company with a rock-solid habit. Havertys Furniture Companies (NYSE: HVT) just announced its latest cash dividend, cementing a tradition that's been rolling since 1935. They're dropping $0.33 per share on the common stock and $0.31 on the Class A common stock. It's set to hit investors' pockets by December 9,...

Continue Reading
Koppers Faces Investigation: Investors Cautious Amid Probe

Updated Category News Views 128

Deep Dive: Koppers' Financial Turmoil When a company throws a financial party, you don't expect the hangover to come in the form of an investigation notice. That’s what’s brewing over at Koppers Holdings Inc., leading many seasoned investors to take a hard, scrutinizing look at the books. The latest buzz? An inquiry into whether the company gave its investors the full...

Continue Reading
Tenax Therapeutics Faces Legal Heat After Stock Plunge

Updated Category News Views 92

Investors' Nerves Tested as Tenax Takes a Nosedive Holy smokes! When a biotech company like Tenax Therapeutics, Inc. (NASDAQ: TENX) detonates like a forgotten fireworks stash, investors have every right to get itchy. Tenax’s shocking announcement that their Phase 3 LEVEL trial for TNX-103 flopped has sparked more than just shareholder anxiety. It’s ignited a...

Continue Reading
Koppers Navigates Q3: Margins Squeeze Amid Growth

Updated Category News Views 110

Investing in Koppers: A Mixed Bag in Q3 Well, it appears Koppers (NYSE: KOP) is doing a bit of a dance this quarter—some smooth steps, but a few stumbles in the rhythm when it comes to margins. The hardwood numbers tell an interesting tale, so let's break it down. Sales Edge Up, But Margins Suffer Koppers clocked in net sales of $499.1 million for the third quarter of...

Continue Reading
Encompass Health Faces Uncertain Future with Sea Pines

Updated Category News Views 119

Unexpected Downpour Closes Sea Pines They say when it rains, it pours. That's not just true in life, but as it happens, it's quite literal in Melbourne, Florida. A deluge of biblical proportions forced an immediate lockdown of the Sea Pines Rehabilitation Hospital. Flooded to the gills, this once stalwart institution finds its doors shuttered indefinitely. It's a...

Continue Reading
Clean Energy: How COP31 Can Change the Future

Updated Category News Views 141

Global Warming: A Battle Heating Up Fast It's like trying to run uphill while carrying the baggage of outdated promises. We’ve got business bigwigs rallying at COP31, demanding the world to get serious about clean energy. If they don’t, we're looking at warming rocketing up to 2.6°C come year 2100. Who's listening though? The Call for Clean Electrification This mob,...

Continue Reading

Top 5 Most Recently Viewed Articles

Growing Demand in Pharmaceutical Excipients Market by 2031

Updated Category News Views 182

Let’s cut to the chase—the pharmaceutical excipients market is heating up. It's not just a smattering of growth here and there; we’re talking about a projected value that’s set to smash through USD 17.13 billion by 2031. That’s a juicy compound annual growth rate (CAGR) of 6.8% from 2024 to 2031 according to SkyQuest Technology. Why the Surge? What's fueling...

Continue Reading
Natural Retreats Enhances Guest Experience with Track Software

Updated Category News Views 354

Natural Retreats Elevates Guest Experience with New Tech Natural Retreats, a leader in the luxury vacation rental market, is making waves with its recent partnership with Track Hospitality Software. This collaboration marks a pivotal shift in how the company operates, ensuring that customer service reaches new heights. By adopting Track's cloud-based property management...

Continue Reading
Lower Factory Input Prices Signal Inflation Relief

Updated Category Economy Views 323

U.S. Manufacturing Sector Contracts for Third Consecutive Month June's U.S. manufacturing sector contracted for the third month running. From 48.7 in May, the Institute for Supply Management (ISM) recorded that its manufacturing PMI dropped to 48.5 in June. A PMI reading less than fifty suggests contraction. Ten percent or so of the U.S. economy is manufacturing....

Continue Reading
Investors Brace for Talen Energy's Earning Report This Week

Updated Category News Views 159

Talen Energy: Prepping for the Earnings Showdown Pencil this one in: February 26, 2026. That’s the big day when Talen Energy (NASDAQ:TLN) rolls out its quarterly earnings report. Investors are chomping at the bit, as EPS is projected to hit a solid $3.68. Get your game faces on folks, because this one could shake up sentiment across the board. The Whisperer’s Corner:...

Continue Reading
Legal Insights: Sage Therapeutics Under Investigation for Alleged Misconduct

Updated Category News Views 119

Understanding the Investigation Surrounding Sage Therapeutics The legal world is buzzing with developments concerning Sage Therapeutics, Inc. (NASDAQ: SAGE), a prominent name in the pharmaceutical industry. Recently, Faruqi & Faruqi, LLP—a respected national securities law firm—has ramped up efforts to investigate potential claims on behalf of investors interested in...

Continue Reading